RBCC establishes headquarters of new biotechnology division in Houston

Rainbow Coral Corp. (OTCBB:RBCC) announced today that it has established the headquarters of its new biotechnology division—Rainbow BioSciences, LLC—in Houston, Texas, home of the world's largest medical complex.

"We targeted Houston from the beginning due to its amazingly large and diverse medical research community based in the Texas Medical Center," said RBCC CEO Patrick Brown. "The opportunities in Houston to develop new R&D partnerships and breakthroughs are unmatched anywhere else in the Southern U.S. We're very excited to set up shop and forge ahead with our new biotech initiatives."

With over $1.8 billion in annual academic research investments and over 160 life sciences companies, Houston attracts venture capitalists from across the nation to invest in the growing life sciences industry there.

"The city is the perfect incubator for a growing company like ours," Brown said. "We look forward to developing new relationships with the researchers and investors who will help us develop the biotech solutions to a host of pressing wellness issues."

Source:

Rainbow Coral Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer signs therapeutic development agreement with Invizius